Venous thromboembolism in patients with cholangiocarcinoma: Focus on risk factors and impact on survival

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 4, 2012, Pages 444-449

  Jeon, Hye Kyung ^a   Kim, Dong Uk ^a   Baek, Dong Hoon ^a   Ha, Dong Woo ^a   Lee, Bong Eun ^a   Ryu, Dong Yup ^a   Cheong, Jae Hoon ^a   Kim, Gwang Ha ^a   Song, Geun Am ^a   Jang, Ae Lee ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Cholangiocarcinoma; Risk factor; Survival; Venous thromboembolism

Indexed keywords

C REACTIVE PROTEIN; CAPECITABINE; CISPLATIN; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; UFT;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; FEMALE; HEPATIN VEIN THROMBOSIS; HUMAN; INFERIOR CAVA VEIN THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; C-REACTIVE PROTEIN; CHOLANGIOCARCINOMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84859306114     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328350f93c     Document Type: Article

References (31)

1. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003; 349:109-111. (Pubitemid 36818779)
2. Bick RL. Cancer-associated thrombosis: focus on extended therapy with dalteparin. J Support Oncol 2006; 4:115-120.
3. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 (Suppl 6):vi1-vi9. (Pubitemid 35216840)
4. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1998; 48:6-29.
5. Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW, et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci 2010; 25:1011-1016.
6. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Di 2010; 42:253-260.
7. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40:472-477. (Pubitemid 38230849)
8. West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006; 94:1751-1758. (Pubitemid 43924943)
9. Jang JW, Yeo CD, Kim JD, Bae SH, Choi JY, Jung ES, et al. Trousseau's syndrome in association with cholangiocarcinoma: positive tests for coagulation factors and anticardiolipin antibody. J Korean Med Sci 2006; 21:155-159. (Pubitemid 43269304)
10. Tasi SH, Juan CJ, Dai MS, Kao WY. Trousseau's syndrome related to adenocarcinoma of the colon and cholangiocarcinoma. Eur J Neurol 2004; 11:493-496.
11. Hernandez JL, Riancho JA, Gonzalez-Macias J. Cholangiocarcinoma presenting as Trousseaus syndrome. Am J Gastroenterol 1998; 93:847-848.
12. Trousseau A. Phlegmasia alba dolens Clinique Medicale de l'Hotel-Dieu de Paris. Vol. 3, 2nd ed. Paris: JB Bailliere; 1865, pp. 654-712.
13. Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56:1-37. (Pubitemid 8029158)
14. Donati MB. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74:278-281.
15. Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, et al. Venous thromboembolic disease. J Natl Compr Canc Netw 2011; 9:714-777.
16. Connolly GC, Chen R, Hyrien O, Mantry P, Bozorgzadeh A, Abt P, et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res 2008; 122:299-306. (Pubitemid 351888883)
17. Kar SP, Bhosale P, Overman MJ, Weatherly J, Xiao L, Wolff RA, et al. Role of anticoagulation in patients with advanced pancreatic cancer with splanchnic venous thrombosis. J Clin Oncol 2011; 29 (Suppl):e14622.
18. Rodrigues CA, Ferrarotto R, Kalil Filho R, Novis YA, Hoff PM. Venous thromboembolism and cancer: a systematic review. J Thromb Thrombolysis 2010; 30:67-78.
19. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic, mutations, and the risk of venous thrombosis. JAMA 2005; 293:715-722. (Pubitemid 40216041)
20. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166:458-464.
21. Gale AJ, Gordon SG. Update on tumor cell procoagulant factors. Acta Haematol 2001; 106:25-32. (Pubitemid 32830513)
22. Otten HM, Mathijssen J, ten Cate H, Soesan M, Inghels M, Richel DJ, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004; 164:190-194. (Pubitemid 38140406)
23. Wang J, Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. Br J Haematol 2001; 115:382-391. (Pubitemid 34203507)
24. Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 1992; 81:480-488.
25. Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985; 42:296-300. (Pubitemid 16244064)
26. Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10- year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol) 2007; 19:143-149. (Pubitemid 46187488)
27. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapyassociated thrombosis. Blood 2008; 111:4902-4907.
28. Simanek R, Vormittag R, Ay C, Alguel G, Dunkler D, Schwarzinger I, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 8:114-120, [Epub 2 November 2009].
29. Trujillo-Santos J, Di Micco P, Iannuzzo M, Lecumberri R, Guijarro R, Madridano O, Monreal M. RIETE investigators. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism: findings from the RIETE registry. Thromb Haemost 2008; 100:905-911.
30. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343:1846-1850. (Pubitemid 32104130)
31. Lee AY. Treatment of venous thromboembolism in cancer patients. Best Pract Res Clin Haematol 2009; 22:93-101.